These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 21856864)

  • 1. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice.
    Yu Y; Wang D; Liu C; Kaosaard K; Semple K; Anasetti C; Yu XZ
    Blood; 2011 Nov; 118(18):5011-20. PubMed ID: 21856864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th1 and Th17 join forces for acute GVHD.
    Teshima T
    Blood; 2011 Nov; 118(18):4765-7. PubMed ID: 22053173
    [No Abstract]   [Full Text] [Related]  

  • 3. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells.
    Long J; Chang L; Shen Y; Gao WH; Wu YN; Dou HB; Huang MM; Wang Y; Fang WY; Shan JH; Wang YY; Zhu J; Chen Z; Hu J
    J Immunol; 2015 Aug; 195(4):1849-57. PubMed ID: 26179902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double deficiency for RORγt and T-bet drives Th2-mediated allograft rejection in mice.
    Sabet-Baktach M; Eggenhofer E; Rovira J; Renner P; Lantow M; Farkas SA; Malaisé M; Edtinger K; Shaotang Z; Koehl GE; Dahlke MH; Schlitt HJ; Geissler EK; Kroemer A
    J Immunol; 2013 Oct; 191(8):4440-6. PubMed ID: 24058178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function.
    Fu J; Wang D; Yu Y; Heinrichs J; Wu Y; Schutt S; Kaosaard K; Liu C; Haarberg K; Bastian D; McDonald DG; Anasetti C; Yu XZ
    J Immunol; 2015 Jan; 194(1):388-97. PubMed ID: 25404360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
    Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
    Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
    Yao Y; Wang L; Zhou J; Zhang X
    J Transl Med; 2017 Feb; 15(1):28. PubMed ID: 28183349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice.
    Wu Y; Bastian D; Schutt S; Nguyen H; Fu J; Heinrichs J; Xia C; Yu XZ
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1195-204. PubMed ID: 25846718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease.
    Iclozan C; Yu Y; Liu C; Liang Y; Yi T; Anasetti C; Yu XZ
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):170-8. PubMed ID: 19804837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.
    Betts BC; Locke FL; Sagatys EM; Pidala J; Walton K; Menges M; Reff J; Saha A; Djeu JY; Kiluk JV; Lee MC; Kim J; Kang CW; Tang CH; Frieling J; Lynch CC; List A; Rodriguez PC; Blazar BR; Conejo-Garcia JR; Del Valle JR; Hu CC; Anasetti C
    Front Immunol; 2018; 9():2887. PubMed ID: 30574153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
    Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice.
    Bending D; De la Peña H; Veldhoen M; Phillips JM; Uyttenhove C; Stockinger B; Cooke A
    J Clin Invest; 2009 Mar; 119(3):565-72. PubMed ID: 19188681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17.
    Nishimori H; Maeda Y; Teshima T; Sugiyama H; Kobayashi K; Yamasuji Y; Kadohisa S; Uryu H; Takeuchi K; Tanaka T; Yoshino T; Iwakura Y; Tanimoto M
    Blood; 2012 Jan; 119(1):285-95. PubMed ID: 22077062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconstitution of interleukin-17-producing T helper cells after allogeneic hematopoietic cell transplantation.
    Bahr F; Wehner R; Platzbecker U; Wermke M; Shayegi N; Middeke JM; Röllig C; Schetelig J; Ehninger G; Schmitz M; Bornhäuser M; Tuve S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):357-65. PubMed ID: 23207644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.
    Nguyen H; Alawieh A; Bastian D; Kuril S; Dai M; Daenthanasanmak A; Zhang M; Iamsawat S; Schutt SD; Wu Y; Sleiman MM; Shetty A; Atkinson C; Sun S; Varela JC; Tomlinson S; Yu XZ
    Clin Cancer Res; 2020 Jul; 26(13):3481-3490. PubMed ID: 31919135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery Profiles of T-Cell Subsets Following Low-Dose Total Body Irradiation and Improvement With Cinnamon.
    Zheng X; Guo Y; Wang L; Zhang H; Wang S; Wang L; An L; Zhou X; Li X; Yao C
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1118-26. PubMed ID: 26475064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.